Verona Pharma plc financial data

Symbol
VRNA on Nasdaq
Location
3 More London Riverside, London, United Kingdom
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.05K % -32.5%
Quick Ratio 14.8 %
Debt-to-equity 133 % +187%
Return On Equity -38.7 % +30.2%
Return On Assets -16.6 % +56.1%
Operating Margin -25.3 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 681M shares +5%
Common Stock, Shares, Outstanding 688M shares +6.06%
Entity Public Float 1.1B USD -26.7%
Common Stock, Value, Issued 45M USD +5.26%
Weighted Average Number of Shares Outstanding, Basic 685M shares +5.7%
Weighted Average Number of Shares Outstanding, Diluted 727M shares +12.2%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 222M USD
Research and Development Expense 13M USD -33.2%
General and Administrative Expense 222M USD +127%
Operating Income (Loss) -56M USD +57.2%
Nonoperating Income (Expense) -16.9M USD -331%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -72.9M USD +41%
Income Tax Expense (Benefit) 8.24M USD +369%
Net Income (Loss) Attributable to Parent -81.2M USD +35.3%
Earnings Per Share, Basic 0 USD/shares +40%
Earnings Per Share, Diluted 0 USD/shares +40%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 438M USD +8.26%
Accounts Receivable, after Allowance for Credit Loss, Current 82.9M USD
Inventory, Net 8.61M USD
Other Assets, Current 3.87M USD +50.3%
Assets, Current 549M USD +31.8%
Property, Plant and Equipment, Net 991K USD +2152%
Operating Lease, Right-of-Use Asset 1.57M USD -29.8%
Goodwill 545K USD 0%
Assets 573M USD +32%
Accounts Payable, Current 3.43M USD -17.3%
Employee-related Liabilities, Current 7.93M USD +100%
Accrued Liabilities, Current 43.3M USD +121%
Contract with Customer, Liability, Current 0 USD
Liabilities, Current 51.2M USD +5.98%
Contract with Customer, Liability, Noncurrent 105M USD
Operating Lease, Liability, Noncurrent 926K USD -37.3%
Liabilities 295M USD +10.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax -4.6M USD 0%
Retained Earnings (Accumulated Deficit) -567M USD -16.9%
Stockholders' Equity Attributable to Parent 278M USD +65.4%
Liabilities and Equity 573M USD +32%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -11.6M USD +15.1%
Net Cash Provided by (Used in) Financing Activities 13.5M USD
Net Cash Provided by (Used in) Investing Activities -535K USD -3244%
Common Stock, Shares, Issued 703M shares +5.32%
Common Stock, Par or Stated Value Per Share 0.05 GBP/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.66M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 438M USD +8.26%
Interest Paid, Excluding Capitalized Interest, Operating Activities 10.2M USD +988%
Deferred Tax Assets, Valuation Allowance 98.5M USD +77.4%
Deferred Tax Assets, Gross 181M USD +65.2%
Operating Lease, Liability 2.36M USD -20.1%
Payments to Acquire Property, Plant, and Equipment 535K USD +3244%
Lessee, Operating Lease, Liability, to be Paid 2.74M USD -23.8%
Operating Lease, Liability, Current 1.01M USD -1.65%
Lessee, Operating Lease, Liability, to be Paid, Year Two 841K USD -0.12%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.11M USD -5.28%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 375K USD -40.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 782K USD -0.76%
Deferred Tax Assets, Operating Loss Carryforwards 65.3M USD +20.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 784K USD
Additional Paid in Capital 806M USD +30.7%
Depreciation, Depletion and Amortization 295K USD +12.2%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 93.7M USD +218%
Interest Expense 13.8M USD +732%